Literature DB >> 10094960

Characterization of the human multidrug resistance protein isoform MRP3 localized to the basolateral hepatocyte membrane.

J König1, D Rost, Y Cui, D Keppler.   

Abstract

Several members of the multidrug resistance protein (MRP) family are expressed in the liver. Adenosine triphosphate (ATP)-dependent transport of glutathione and glucuronoside conjugates across the hepatocyte canalicular membrane is mediated by the apical MRP isoform, MRP2 (APMRP), also known as canalicular multispecific organic anion transporter (cMOAT). We have cloned an additional MRP isoform, MRP3, from human liver and localized it to the basolateral membrane domain of hepatocytes. Basolateral MRP (BLMRP) is composed of 1,527 amino acids and encoded by 4,581 base pairs of complementary DNA. Northern blotting of various human tissues indicated an expression of MRP3 in the liver, colon, pancreas, and, at a lower level, in the kidney. The amino acid identity of MRP3 with MRP1 and MRP2 is 58% and 48%, respectively. These three isoforms, encoded by genes on different chromosomes, have a similar predicted topology of transmembrane segments and ATP-binding domains. Antibodies raised against two peptide sequences of MRP3 that are not shared by other MRP family members detected recombinant MRP3 expressed in polarized MDCK cells. Both antibodies served to localize MRP3 to the basolateral membrane of hepatocytes. Double-label immunofluorescence microscopy confirmed that MRP3 was not detectable in the canalicular membrane domain. A particularly strong expression of the MRP3 protein was observed in the basolateral hepatocyte membrane of two patients with Dubin-Johnson syndrome who are deficient in MRP2. These results indicate that the basolateral MRP isoform, MRP3, may be upregulated when the canalicular secretion of anionic conjugates by MRP2 is impaired.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10094960     DOI: 10.1002/hep.510290404

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  69 in total

Review 1.  Hepatocellular transport proteins and their role in liver disease.

Authors:  C Stanca; D Jung; P J Meier; G A Kullak-Ublick
Journal:  World J Gastroenterol       Date:  2001-04       Impact factor: 5.742

Review 2.  Drug transporters in pharmacokinetics.

Authors:  Ernst Petzinger; Joachim Geyer
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-03-11       Impact factor: 3.000

Review 3.  MRP subfamily transporters and resistance to anticancer agents.

Authors:  G D Kruh; H Zeng; P A Rea; G Liu; Z S Chen; K Lee; M G Belinsky
Journal:  J Bioenerg Biomembr       Date:  2001-12       Impact factor: 2.945

4.  Nuclear receptors RXRalpha:RARalpha are repressors for human MRP3 expression.

Authors:  Wensheng Chen; Shi-Ying Cai; Shuhua Xu; Lee A Denson; Carol J Soroka; James L Boyer
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2007-02-01       Impact factor: 4.052

Review 5.  Multidrug Resistance Proteins (MRPs) and Cancer Therapy.

Authors:  Yun-Kai Zhang; Yi-Jun Wang; Pranav Gupta; Zhe-Sheng Chen
Journal:  AAPS J       Date:  2015-04-04       Impact factor: 4.009

Review 6.  A perspective on efflux transport proteins in the liver.

Authors:  K Köck; K L R Brouwer
Journal:  Clin Pharmacol Ther       Date:  2012-09-05       Impact factor: 6.875

Review 7.  Multidrug resistance-associated proteins 3, 4, and 5.

Authors:  Piet Borst; Cornelia de Wolf; Koen van de Wetering
Journal:  Pflugers Arch       Date:  2006-04-04       Impact factor: 3.657

8.  Transport of bile acids in multidrug-resistance-protein 3-overexpressing cells co-transfected with the ileal Na+-dependent bile-acid transporter.

Authors:  Noam Zelcer; Tohru Saeki; Ilse Bot; Annemieke Kuil; Piet Borst
Journal:  Biochem J       Date:  2003-01-01       Impact factor: 3.857

9.  Role of multidrug transporters in neurotherapeutics.

Authors:  Manna Jose; Sanjeev V Thomas
Journal:  Ann Indian Acad Neurol       Date:  2009-04       Impact factor: 1.383

10.  Induction of hepatic multidrug resistance-associated protein 3 by ethynylestradiol is independent of cholestasis and mediated by estrogen receptor.

Authors:  María L Ruiz; Juan P Rigalli; Agostina Arias; Silvina Villanueva; Claudia Banchio; Mary Vore; Aldo D Mottino; Viviana A Catania
Journal:  Drug Metab Dispos       Date:  2012-10-17       Impact factor: 3.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.